Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
What is Erelzi and how is it used?
Erelzi is a prescription medicine called a Tumor Necrosis Factor (TNF) blocker. Erelzi is used to treat:
You may continue to use other medicines that help treat your condition while taking Erelzi, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and prescription steroids, as recommended by your healthcare provider.
Erelzi can help reduce joint damage and the signs and symptoms of the above-mentioned diseases. People with these diseases have too much of a protein called tumor necrosis factor (TNF), which is made by your immune system. Erelzi can reduce the effect of TNF in the body and block the damage that too much TNF can cause, but it can also lower the ability of your immune system to fight infections.
What are the possible side effects of Erelzi?
Erelzi can cause serious side effects including:
Common side effects of Erelzi include:
These are not all the side effects with Erelzi. Tell your healthcare provider about any side effect that bothers you or does not go away.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
WARNING
SERIOUS INFECTIONS AND MALIGNANCIES
Patients treated with etanercept products are at increased risk for developing serious infections that may lead to hospitalization or death [see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS]. Most patients treated with etanercept products who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.
ERELZI should be discontinued if a patient develops a serious infection or sepsis.
Reported infections include:
The risks and benefits of treatment with ERELZI should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.
Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with ERELZI, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.
Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including etanercept products.
ERELZI (etanercept-szzs), a tumor necrosis factor (TNF) blocker, is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept-szzs contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept-szzs is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids and has an apparent molecular weight of approximately 150 kilodaltons.
ERELZI (etanercept-szzs) Injection in the single-dose prefilled syringe with BD UltraSafe Passive Needle Guard and the single-dose prefilled Sensoready Pen is clear and colorless to slightly yellow, sterile, preservative-free, and is formulated at pH 6.3 ± 0.2. ERELZI is for subcutaneous use.
Table 5: Contents of ERELZI
| Presentation | Active Ingredient Content | Inactive Ingredients Content |
| Etanercept-szzs 50 mg prefilled syringe with BD UltraSafe Passive Needle Guard and Sensoready Pen | 50 mg etanercept-szzs in 1 mL | 0.786 mg citric acid 13.52 mg sodium citrate 1.5 mg sodium chloride 10 mg sucrose 4.6 mg lysine |
| Etanercept-szzs 25 mg prefilled syringe with BD UltraSafe Passive Needle Guard | 25 mg etanercept-szzs in 0.5 mL | 0.393 mg citric acid 6.76 mg sodium citrate 0.75 mg sodium chloride 5 mg sucrose 2.3 mg lysine |
ERELZI is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (RA). ERELZI can be initiated in combination with methotrexate (MTX) or used alone.
ERELZI is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older.
ERELZI is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis (PsA). ERELZI can be used with or without methotrexate.
ERELZI is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (AS).
ERELZI is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.
ERELZI is administered by subcutaneous injection.
Table 1: Dosing and
Administration for Adult Patients
| Patient Population | Recommended Dosage Strength and Frequency |
| Adult RA, AS, and PsA | 50 mg weekly |
| Adult PsO | Starting Dose: 50 mg twice weekly for 3 months Maintenance Dose: 50 mg once weekly |
See the ERELZI (etanercept-szzs) “Instructions for Use” insert for detailed information on injection site selection and dose administration. [see Preparation of ERELZI and PATIENT INFORMATION]
Methotrexate, glucocorticoids, salicylates, nonsteroidal anti-inflammatory drugs (NSAIDs), or analgesics may be continued during treatment with ERELZI. Based on a study of 50 mg etanercept twice weekly in patients with RA that suggested higher incidence of adverse reactions but similar American College of Rheumatology (ACR) response rates, doses higher than 50 mg per week are not recommended.
In addition to the 50 mg twice weekly recommended starting dose, starting doses of 25 mg or 50 mg per week were shown to be efficacious. The proportion of responders was related to etanercept dosage [see Clinical Studies].
ERELZI is administered by subcutaneous injection.
Table 2: Dosing and Administration for Juvenile
Idiopathic Arthritis
| Pediatric Patients Weight | Recommended Dose |
| 63 kg (138 pounds) or more | 50 mg weekly |
Note: There is no dosage form for ERELZI that allows weight based dosing for pediatric patients below 63 kg.
Doses of etanercept products higher than those described in Table 2 have not been studied in pediatric patients.
In JIA patients, glucocorticoids, NSAIDs, or analgesics may be continued during treatment with ERELZI.
ERELZI is intended for use under the guidance and supervision of a physician. Patients may self-inject when deemed appropriate and if they receive medical follow-up, as necessary. Patients should not self-administer until they receive proper training in how to prepare and administer the correct dose. Administer injections subcutaneously in the thigh, abdomen, or outer area of the upper arm.
The ERELZI (etanercept-szzs) “Instructions for Use” insert for each presentation contains more detailed instructions on injection site selection and the preparation of ERELZI.
Leave ERELZI at room temperature for about 15 to 30 minutes before injecting. DO NOT remove the needle cover while allowing the prefilled syringe to reach room temperature.
Inspect visually for particulate matter and discoloration prior to administration. There may be small white particles of protein in the solution. This is not unusual for proteinaceous solutions. The solution should not be used if discolored or cloudy, or if foreign particulate matter is present.
Prior to initiating ERELZI and periodically during therapy, patients should be evaluated for active tuberculosis and tested for latent infection [see WARNINGS AND PRECAUTIONS].
ERELZI is a clear and colorless to slightly yellow solution available as:
Administration of one 50 mg ERELZI prefilled syringe with BD UltraSafe Passive Needle Guard or one ERELZI Sensoready Pen provides a dose equivalent to two 25 mg ERELZI prefilled syringes with BD UltraSafe Passive Needle Guard.
Each ERELZI (etanercept-szzs) Injection single-dose prefilled syringe with BD UltraSafe Passive Needle Guard and ERELZI single-dose prefilled Sensoready Pen contains clear and colorless to slightly yellow solution containing 25 mg/0.5 mL or 50 mg/mL of etanercept-szzs in a single-dose syringe with a 27-gauge, ½-inch needle.
| 50 mg/mL single-dose prefilled syringe | Carton of 4 | NDC 61314-821-04 |
| 50 mg/mL single-dose prefilled Sensoready Pen | Carton of 4 | NDC 61314-832-04 |
| 25 mg/0.5 mL single-dose prefilled syringe | Carton of 4 | NDC 61314-843-04 |
ERELZI should be refrigerated at 36°F to 46°F (2°C to 8°C). Do not use ERELZI beyond the expiration date stamped on the carton or barrel label. DO NOT SHAKE. Store ERELZI in the original carton to protect from light or physical damage.
For convenience, storage of individual syringes or Sensoready Pens at room temperature between 68°F to 77°F (20°C to 25°C) for a maximum single period of 28 days is permissible, with protection from light and sources of heat. Once a syringe or Sensoready Pen has been stored at room temperature, it should not be placed back into the refrigerator. If not used within 28 days at room temperature, the syringe or Sensoready Pens should be discarded. Do not store ERELZI in extreme heat or cold. DO NOT FREEZE. Keep out of the reach of children.
Manufactured by: Sandoz Inc. Princeton, NJ 08540 US License No. 2003. At: Sandoz GmbH Langkampfen, Austria Product of Austria. Revised: Oct 2019
The following serious adverse reactions are discussed in greater detail in other sections of the labeling:
Across clinical studies and postmarketing experience, the most serious adverse reactions with etanercept were infections, neurologic events, CHF, and hematologic events [see WARNINGS AND PRECAUTIONS]. The most common adverse reactions with etanercept were infections and injection site reactions.
Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not predict the rates observed in clinical practice.
The data described below reflect exposure to etanercept in 2219 adult patients with RA followed for up to 80 months, in 182 patients with PsA for up to 24 months, in 138 patients with AS for up to 6 months, and in 1204 adult patients with PsO for up to 18 months.
In controlled trials, the proportion of etanercept-treated patients who discontinued treatment due to adverse events was approximately 4% in the indications studied.
In general, the adverse reactions in pediatric patients were similar in frequency and type as those seen in adult patients [see WARNINGS AND PRECAUTIONS, Use In Specific Populations and Clinical Studies].
In open-label clinical studies of children with JIA, adverse reactions reported in those ages 2 to 4 years were similar to adverse reactions reported in older children.
Infections, including viral, bacterial, and fungal infections, have been observed in adult and pediatric patients. Infections have been noted in all body systems and have been reported in patients receiving etanercept alone or in combination with other immunosuppressive agents.
In controlled portions of trials, the types and severity of infection were similar between etanercept and the respective control group (placebo or MTX for RA and PsA patients) in RA, PsA, AS, and PsO patients. Rates of infections in RA and adult PsO patients are provided in Table 3 and Table 4, respectively. Infections consisted primarily of upper respiratory tract infection, sinusitis and influenza.
In controlled portions of trials in RA, PsA, AS, and PsO, the rates of serious infection were similar (0.8% in placebo, 3.6% in MTX, and 1.4% in etanercept/etanercept + MTX-treated groups). In clinical trials in rheumatologic indications, serious infections experienced by patients have included, but are not limited to, pneumonia, cellulitis, septic arthritis, bronchitis, gastroenteritis, pyelonephritis, sepsis, abscess and osteomyelitis. In clinical trials in adult PsO patients, serious infections experienced by patients have included, but are not limited to, pneumonia, cellulitis, gastroenteritis, abscess and osteomyelitis. The rate of serious infections was not increased in open-label extension trials and was similar to that observed in etanerceptand placebo-treated patients from controlled trials.
In 66 global clinical trials of 17,505 patients (21,015 patient-years of therapy), tuberculosis was observed in approximately 0.02% of patients. In 17,696 patients (27,169 patient-years of therapy) from 38 clinical trials and 4 cohort studies in the U.S. and Canada, tuberculosis was observed in approximately 0.006% of patients. These studies include reports of pulmonary and extrapulmonary tuberculosis [see WARNINGS AND PRECAUTIONS].
The types of infections reported in pediatric patients were generally mild and consistent with those commonly seen in the general pediatric population. Two JIA patients developed varicella infection and signs and symptoms of aseptic meningitis, which resolved without sequelae.
In placebo-controlled trials in rheumatologic indications, approximately 37% of patients treated with etanercept developed injection site reactions. In controlled trials in patients with PsO, 15% of adult patients treated with etanercept developed injection site reactions during the first 3 months of treatment. All injection site reactions were described as mild to moderate (erythema, itching, pain, swelling, bleeding, bruising) and generally did not necessitate drug discontinuation. Injection site reactions generally occurred in the first month and subsequently decreased in frequency. The mean duration of injection site reactions was 3 to 5 days. Seven percent of patients experienced redness at a previous injection site when subsequent injections were given.
Table 3 summarizes adverse reactions reported in adult RA patients. The types of adverse reactions seen in patients with PsA or AS were similar to the types of adverse reactions seen in patients with RA.
Table 3: Percent of Adult RA Patients Experiencing
Adverse Reactions in Controlled Clinical Trials
| Reaction | Placebo Controlleda (Studies I, II and a Phase 2 Study) | Active Controlledb (Study III) | ||
| Placebo (N= 152) |
Etanerceptc (N= 349) |
MTX (N= 217) |
Etanerceptc (N= 415) |
|
| Percent of Patients | Percent of Patients | |||
| Infectiond (total) | 39 | 50 | 86 | 81 |
| Upper Respiratory Infectionse | 30 | 38 | 70 | 65 |
| Non-upper Respiratory Infections | 15 | 21 | 59 | 54 |
| Injection Site Reactions | 11 | 37 | 18 | 43 |
| Diarrhea | 9 | 8 | 16 | 16 |
| Rash | 2 | 3 | 19 | 13 |
| Pruritus | 1 | 2 | 5 | 5 |
| Pyrexia | - | 3 | 4 | 2 |
| Urticaria | 1 | - | 4 | 2 |
| Hypersensitivity | - | - | 1 | 1 |
| aIncludes data from the 6-month study in which
patients received concurrent MTX therapy in both arms. bStudy duration of 2 years. cAny dose.dIncludes bacterial, viral and fungal infections. eMost frequent Upper Respiratory Infections were upper respiratory tract infection, sinusitis, and influenza. |
||||
In placebo-controlled adult PsO trials, the percentages of patients reporting adverse reactions in the 50 mg twice a week dose group were similar to those observed in the 25 mg twice a week dose group or placebo group.
Table 4 summarizes adverse reactions reported in adult PsO patients from Studies I and II.
Table 4: Percent of Adult
PsO Patients Experiencing Adverse Reactions in Placebo-Controlled Portions of
Clinical Trials (Studies I & II)
| Reaction | Placebo (N= 359) |
Etanercepta (N= 876) |
| Percent of Patients | ||
| Infectionb (total) | 28 | 27 |
| Non-upper Respiratory Infections | 14 | 12 |
| Upper Respiratory Infectionsc | 17 | 17 |
| Injection Site Reactions | 6 | 15 |
| Diarrhea | 2 | 3 |
| Rash | 1 | 1 |
| Pruritus | 2 | 1 |
| Urticaria | - | 1 |
| Hypersensitivity | - | 1 |
| Pyrexia | 1 | - |
| aIncludes 25 mg subcutaneous (SC) once weekly
(QW), 25 mg SC twice weekly (BIW), 50 mg SC QW, and 50 mg SC BIW doses. bIncludes bacterial, viral and fungal infections. cMost frequent Upper Respiratory Infections were upper respiratory tract infection, nasopharyngitis, and sinusitis. |
||
As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies or to other etanercept products may be misleading.
Patients with RA, PsA, AS or PsO were tested at multiple time points for antibodies to etanercept. Antibodies to the TNF receptor portion or other protein components of etanercept were detected at least once in sera of approximately 6% of adult patients with RA, PsA, AS or PsO. These antibodies were all non-neutralizing. Results from JIA patients were similar to those seen in adult RA patients treated with etanercept.
In adult PsO studies that evaluated the exposure of etanercept for up to 120 weeks, the percentage of patients testing positive at the assessed time points of 24, 48, 72 and 96 weeks ranged from 3.6%-8.7% and were all non-neutralizing. The percentage of patients testing positive increased with an increase in the duration of study; however, the clinical significance of this finding is unknown. No apparent correlation of antibody development to clinical response or adverse events was observed. The immunogenicity data of etanercept beyond 120 weeks of exposure are unknown.
The data reflect the percentage of patients whose test results were considered positive for antibodies to etanercept in an ELISA assay, and are highly dependent on the sensitivity and specificity of the assay.
Patients with RA had serum samples tested for autoantibodies at multiple time points. In RA Studies I and II, the percentage of patients evaluated for antinuclear antibodies (ANA) who developed new positive ANA (titer ≥ 1:40) was higher in patients treated with etanercept (11%) than in placebo-treated patients (5%). The percentage of patients who developed new positive anti-double-stranded DNA antibodies was also higher by radioimmunoassay (15% of patients treated with etanercept compared to 4% of placebo-treated patients) and by Crithidia luciliae assay (3% of patients treated with etanercept compared to none of placebo-treated patients). The proportion of patients treated with etanercept who developed anticardiolipin antibodies was similarly increased compared to placebo-treated patients. In RA Study III, no pattern of increased autoantibody development was seen in etanercept's patients compared to MTX patients [see WARNINGS AND PRECAUTIONS].
Adverse reactions have been reported during post approval use of etanercept products in adults and pediatric patients. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to etanercept exposure.
Adverse reactions are listed by body system below:
| Blood and lymphatic system disorders: | pancytopenia, anemia, leukopenia, neutropenia, thrombocytopenia, lymphadenopathy, aplastic anemia [see WARNINGS AND PRECAUTIONS] |
| Cardiac disorders: | congestive heart failure [see WARNINGS AND PRECAUTIONS] |
| Gastrointestinal disorders: | inflammatory bowel disease (IBD) |
| General disorders: | angioedema, chest pain |
| Hepatobiliary disorders: | autoimmune hepatitis, elevated transaminases, hepatitis B reactivation |
| Immune disorders: | macrophage activation syndrome, systemic vasculitis, sarcoidosis |
| Musculoskeletal and connective tissue disorders: | lupus-like syndrome |
| Neoplasms benign, malignant, and unspecified: | melanoma and non-melanoma skin cancers, Merkel cell carcinoma [see WARNINGS AND PRECAUTIONS] |
| Nervous system disorders: | convulsions, multiple sclerosis, demyelination, optic neuritis, transverse myelitis, paresthesias [see WARNINGS AND PRECAUTIONS] |
| Ocular disorders: | uveitis, scleritis |
| Respiratory, thoracic and mediastinal disorders: | interstitial lung disease |
| Skin and subcutaneous tissue disorders: | cutaneous lupus erythematosus, cutaneous vasculitis (including leukocytoclastic vasculitis), erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, subcutaneous nodule, new or worsening psoriasis (all subtypes including pustular and palmoplantar) |
Opportunistic infections, including atypical mycobacterial infection, herpes zoster, aspergillosis and Pneumocystis jiroveci pneumonia, and protozoal infections have also been reported in postmarketing use.
Rare (< 0.1%) cases of IBD have been reported in JIA patients receiving etanercept, which is not effective for the treatment of IBD.
Specific drug interaction studies have not been conducted with etanercept products.
Most PsA patients receiving etanercept were able to mount effective B-cell immune responses to pneumococcal polysaccharide vaccine, but titers in aggregate were moderately lower and fewer patients had 2-fold rises in titers compared to patients not receiving etanercept. The clinical significance of this is unknown. Patients receiving ERELZI may receive concurrent vaccinations, except for live vaccines. No data are available on the secondary transmission of infection by live vaccines in patients receiving etanercept products.
Patients with a significant exposure to varicella virus should temporarily discontinue ERELZI therapy and be considered for prophylactic treatment with varicella zoster immune globulin [see WARNINGS AND PRECAUTIONS].
In a study in which patients with active RA were treated for up to 24 weeks concurrently with etanercept and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with etanercept alone (0%) [see WARNINGS AND PRECAUTIONS] and did not result in higher ACR response rates compared to etanercept alone. The most common infections consisted of bacterial pneumonia (4 cases) and cellulitis (4 cases). One patient with pulmonary fibrosis and pneumonia died due to respiratory failure. Two percent of patients treated concurrently with etanercept and anakinra developed neutropenia (ANC < 1 x 109/L).
In clinical studies, concurrent administration of abatacept and etanercept resulted in increased incidences of serious adverse events, including infections, and did not demonstrate increased clinical benefit [see WARNINGS AND PRECAUTIONS].
The use of ERELZI in patients receiving concurrent cyclophosphamide therapy is not recommended [see WARNINGS AND PRECAUTIONS].
Patients in a clinical study who were on established therapy with sulfasalazine, to which etanercept was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either etanercept or sulfasalazine alone. The clinical significance of this observation is unknown.
Included as part of the PRECAUTIONS section.
Patients treated with ERELZI are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death. Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF blockers. Patients have frequently presented with disseminated rather than localized disease.
Treatment with ERELZI should not be initiated in patients with an active infection, including clinically important localized infections. Patients greater than 65 years of age, patients with co-morbid conditions, and/or patients taking concomitant immunosuppressants (such as corticosteroids or methotrexate), may be at greater risk of infection. The risks and benefits of treatment should be considered prior to initiating therapy in patients:
Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with ERELZI.
ERELZI should be discontinued if a patient develops a serious infection or sepsis. A patient who develops a new infection during treatment with ERELZI should be closely monitored, undergo a prompt and complete diagnostic workup appropriate for an immunocompromised patient, and appropriate antimicrobial therapy should be initiated.
Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving etanercept products, including patients who have previously received treatment for latent or active tuberculosis. Data from clinical trials and preclinical studies suggest that the risk of reactivation of latent tuberculosis infection is lower with etanercept than with TNF-blocking monoclonal antibodies. Nonetheless, postmarketing cases of tuberculosis reactivation have been reported for TNF blockers, including etanercept products. Tuberculosis has developed in patients who tested negative for latent tuberculosis prior to initiation of therapy. Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating ERELZI and periodically during therapy. Tests for latent tuberculosis infection may be falsely negative while on therapy with ERELZI.
Treatment of latent tuberculosis infection prior to therapy with TNF-blocking agents has been shown to reduce the risk of tuberculosis reactivation during therapy. Induration of 5 mm or greater with tuberculin skin testing should be considered a positive test result when assessing if treatment for latent tuberculosis is needed prior to initiating ERELZI, even for patients previously vaccinated with Bacille Calmette-Guerin (BCG).
Anti-tuberculosis therapy should also be considered prior to initiation of ERELZI in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection. Consultation with a physician with expertise in the treatment of tuberculosis is recommended to aid in the decision whether initiating anti-tuberculosis therapy is appropriate for an individual patient.
Tuberculosis should be strongly considered in patients who develop a new infection during ERELZI treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis.
Cases of serious and sometimes fatal fungal infections, including histoplasmosis, have been reported with TNF blockers, including etanercept products. For patients who reside or travel in regions where mycoses are endemic, invasive fungal infection should be suspected if they develop a serious systemic illness. Appropriate empiric anti-fungal therapy should be considered while a diagnostic workup is being performed. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. When feasible, the decision to administer empiric anti-fungal therapy in these patients should be made in consultation with a physician with expertise in the diagnosis and treatment of invasive fungal infections and should take into account both the risk for severe fungal infection and the risks of anti-fungal therapy. In 38 of etanercept’s clinical trials and 4 cohort studies in all approved indications representing 27,169 patient-years of exposure (17,696 patients) from the United States and Canada, no histoplasmosis infections were reported among patients treated with etanercept.
Treatment with TNF-blocking agents, including etanercept products, has been associated with rare (< 0.1%) cases of new onset or exacerbation of central nervous system demyelinating disorders, some presenting with mental status changes and some associated with permanent disability, and with peripheral nervous system demyelinating disorders. Cases of transverse myelitis, optic neuritis, multiple sclerosis, Guillain-Barre syndromes, other peripheral demyelinating neuropathies, and new onset or exacerbation of seizure disorders have been reported in postmarketing experience with etanercept products therapy. Prescribers should exercise caution in considering the use of ERELZI in patients with preexisting or recent-onset central or peripheral nervous system demyelinating disorders [see ADVERSE REACTIONS].
In the controlled portions of clinical trials of TNF-blocking agents, more cases of lymphoma have been observed among patients receiving a TNF blocker compared to control patients. During the controlled portions of etanercept’s trials in adult patients with RA, AS, and PsA, 2 lymphomas were observed among 3306 etanercept-treated patients versus 0 among 1521 control patients (duration of controlled treatment ranged from 3 to 36 months).
Among 6543 adult rheumatology (RA, PsA, AS) patients treated with etanercept in controlled and uncontrolled portions of clinical trials, representing approximately 12,845 patient-years of therapy, the observed rate of lymphoma was 0.10 cases per 100 patient-years. This was 3-fold higher than the rate of lymphoma expected in the general U.S. population based on the Surveillance, Epidemiology, and End Results (SEER) Database. An increased rate of lymphoma up to several-fold has been reported in the RA patient population, and may be further increased in patients with more severe disease activity.
Among 4410 adult PsO patients treated with etanercept in clinical trials up to 36 months, representing approximately 4278 patient-years of therapy, the observed rate of lymphoma was 0.05 cases per 100 patient-years, which is comparable to the rate in the general population. No cases were observed in etanercept-or placebo-treated patients during the controlled portions of these trials.
Cases of acute and chronic leukemia have been reported in association with postmarketing TNF-blocker use in rheumatoid arthritis and other indications. Even in the absence of TNF-blocker therapy, patients with rheumatoid arthritis may be at higher risk (approximately 2-fold) than the general population for the development of leukemia.
During the controlled portions of etanercept’s trials, 2 cases of leukemia were observed among 5445 (0.06 cases per 100 patient-years) etanercept-treated patients versus 0 among 2890 (0%) control patients (duration of controlled treatment ranged from 3 to 48 months).
Among 15,401 patients treated with etanercept in controlled and open portions of clinical trials representing approximately 23,325 patient-years of therapy, the observed rate of leukemia was 0.03 cases per 100 patient-years.
Information is available from 10,953 adult patients with 17,123 patient-years and 696 pediatric patients with 1282 patient-years of experience across 45 etanercept clinical studies.
For malignancies other than lymphoma and non-melanoma skin cancer, there was no difference in exposure-adjusted rates between etanercept and control arms in the controlled portions of clinical studies for all indications. Analysis of the malignancy rate in combined controlled and uncontrolled portions of studies has demonstrated that types and rates are similar to what is expected in the general U.S. population based on the SEER database and suggests no increase in rates over time. Whether treatment with etanercept products might influence the development and course of malignancies in adults is unknown.
Melanoma and non-melanoma skin cancer has been reported in patients treated with TNF antagonists including etanercept products.
Among 15,401 patients treated with etanercept in controlled and open portions of clinical trials representing approximately 23,325 patient-years of therapy, the observed rate of melanoma was 0.043 cases per 100 patient-years.
Among 3306 adult rheumatology (RA, PsA, AS) patients treated with etanercept in controlled clinical trials representing approximately 2669 patient-years of therapy, the observed rate of NMSC was 0.41 cases per 100 patient-years vs 0.37 cases per 100 patient-years among 1521 control-treated patients representing 1077 patient-years. Among 1245 adult PsO patients treated with etanercept in controlled clinical trials, representing approximately 283 patient-years of therapy, the observed rate of NMSC was 3.54 cases per 100 patient-years vs 1.28 cases per 100 patient-years among 720 control-treated patients representing 156 patient-years.
Postmarketing cases of Merkel cell carcinoma have been reported very infrequently in patients treated with etanercept products.
Periodic skin examinations should be considered for all patients at increased risk for skin cancer.
Malignancies, some fatal, have been reported among children, adolescents, and young adults who received treatment with TNF-blocking agents (initiation of therapy at ≥ 18 years of age), including etanercept products. Approximately half the cases were lymphomas, including Hodgkin’s and non-Hodgkin’s lymphoma. The other cases represented a variety of different malignancies and included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. The malignancies occurred after a median of 30 months of therapy (range 1 to 84 months). Most of the patients were receiving concomitant immunosuppressants. These cases were reported postmarketing and are derived from a variety of sources, including registries and spontaneous postmarketing reports.
In clinical trials of 1140 pediatric patients representing 1927.2 patient-years of therapy, no malignancies, including lymphoma or NMSC, have been reported.
In global postmarketing adult and pediatric use, lymphoma and other malignancies have been reported.
Two clinical trials evaluating the use of etanercept in the treatment of heart failure were terminated early due to lack of efficacy. One of these studies suggested higher mortality in etanercept-treated patients compared to placebo [see ADVERSE REACTIONS]. There have been postmarketing reports of worsening of congestive heart failure (CHF), with and without identifiable precipitating factors, in patients taking etanercept products. There have also been rare (< 0.1%) reports of new onset CHF, including CHF in patients without known preexisting cardiovascular disease. Some of these patients have been under 50 years of age. Physicians should exercise caution when using ERELZI in patients who also have heart failure, and monitor patients carefully.
Rare (< 0.1%) reports of pancytopenia, including very rare (< 0.01%) reports of aplastic anemia, some with a fatal outcome, have been reported in patients treated with etanercept. The causal relationship to therapy with etanercept products remains unclear. Although no high-risk group has been identified, caution should be exercised in patients being treated with ERELZI who have a previous history of significant hematologic abnormalities. All patients should be advised to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection (e.g., persistent fever, bruising, bleeding, pallor) while on ERELZI. Discontinuation of ERELZI therapy should be considered in patients with confirmed significant hematologic abnormalities.
Two percent of patients treated concurrently with etanercept and anakinra developed neutropenia (ANC < 1 x 109 /L). While neutropenic, one patient developed cellulitis that resolved with antibiotic therapy.
Reactivation of hepatitis B in patients who were previously infected with the hepatitis B virus (HBV) and had received concomitant TNF-blocking agents, including very rare cases (< 0.01%) with etanercept, has been reported. In some instances, hepatitis B reactivation occurring in conjunction with TNF-blocker therapy has been fatal. The majority of these reports have occurred in patients concomitantly receiving other medications that suppress the immune system, which may also contribute to hepatitis B reactivation. Patients at risk for HBV infection should be evaluated for prior evidence of HBV infection before initiating TNF-blocker therapy. Prescribers should exercise caution in prescribing TNF blockers in patients previously infected with HBV. Adequate data are not available on the safety or efficacy of treating patients who are carriers of HBV with anti-viral therapy in conjunction with TNF blocker therapy to prevent HBV reactivation. Patients previously infected with HBV and requiring treatment with ERELZI should be closely monitored for clinical and laboratory signs of active HBV infection throughout therapy and for several months following termination of therapy. In patients who develop HBV reactivation, consideration should be given to stopping ERELZI and initiating anti-viral therapy with appropriate supportive treatment. The safety of resuming therapy with etanercept products after HBV reactivation is controlled is not known. Therefore, prescribers should weigh the risks and benefits when considering resumption of therapy in this situation.
Allergic reactions associated with administration of etanercept during clinical trials have been reported in < 2% of patients. If an anaphylactic reaction or other serious allergic reaction occurs, administration of ERELZI should be discontinued immediately and appropriate therapy initiated. Caution: The following components contain dry natural rubber (a derivative of latex), which may cause allergic reactions in individuals sensitive to latex: the needle cap of the prefilled syringe and the internal needle cover within the cap of the Sensoready Pen.
Live vaccines should not be given concurrently with ERELZI. It is recommended that pediatric patients, if possible, be brought up-to-date with all immunizations in agreement with current immunization guidelines prior to initiating ERELZI therapy [see DRUG INTERACTIONS and Use In Specific Populations].
Treatment with ERELZI may result in the formation of autoantibodies [see ADVERSE REACTIONS] and, rarely (< 0.1%), in the development of a lupus-like syndrome or autoimmune hepatitis [see ADVERSE REACTIONS], which may resolve following withdrawal of ERELZI. If a patient develops symptoms and findings suggestive of a lupus-like syndrome or autoimmune hepatitis following treatment with ERELZI, treatment should be discontinued and the patient should be carefully evaluated.
TNF mediates inflammation and modulates cellular immune responses. TNF-blocking agents, including etanercept products, affect host defenses against infections. The effect of TNF inhibition on the development and course of malignancies is not fully understood. In a study of 49 patients with RA treated with etanercept, there was no evidence of depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in enumeration of effector cell populations [see Serious Infections, Malignancies and ADVERSE REACTIONS].
The use of ERELZI in patients with Wegener’s granulomatosis receiving immunosuppressive agents is not recommended. In a study of patients with Wegener’s granulomatosis, the addition of etanercept to standard therapy (including cyclophosphamide) was associated with a higher incidence of non-cutaneous solid malignancies and was not associated with improved clinical outcomes when compared with standard therapy alone [see DRUG INTERACTIONS].
Use of ERELZI with anakinra or abatacept is not recommended [see DRUG INTERACTIONS].
In a study of 48 hospitalized patients treated with etanercept or placebo for moderate to severe alcoholic hepatitis, the mortality rate in patients treated with etanercept was similar to patients treated with placebo at 1 month but significantly higher after 6 months. Physicians should use caution when using ERELZI in patients with moderate to severe alcoholic hepatitis.
Advise the patient and/or caregiver to read FDA-approved patient labeling (Medication Guide and Instructions for Use) before the patient starts using ERELZI, and each time the prescription is renewed, as there may be new information they need to know.
Patients or their caregivers should be provided the ERELZI “Medication Guide” and provided an opportunity to read it and ask questions prior to initiation of therapy. The healthcare provider should ask the patient questions to determine any risk factors for treatment. Patients developing signs and symptoms of infection should seek medical evaluation immediately.
Patients should be advised of the potential benefits and risks of ERELZI. Physicians should instruct their patients to read the Medication Guide before starting ERELZI therapy and to reread each time the prescription is renewed.
Inform patients that ERELZI may lower the ability of their immune system to fight infections. Advise patients of the importance of contacting their doctor if they develop any symptoms of infection, tuberculosis or reactivation of hepatitis B virus infections.
Advise patients to report any signs of new or worsening medical conditions, such as central nervous system demyelinating disorders, heart failure or autoimmune disorders, such as lupus-like syndrome or autoimmune hepatitis. Counsel about the risk of lymphoma and other malignancies while receiving ERELZI. Advise patients to report any symptoms suggestive of a pancytopenia, such as bruising, bleeding, persistent fever or pallor.
Advise patients to seek immediate medical attention if they experience any symptoms of severe allergic reactions. Advise latex-sensitive patients that the following components contain dry natural rubber (a derivative of latex) that may cause allergic reactions in individuals sensitive to latex: the needle cap of the prefilled syringe and the internal needle cover within the cap of the Sensoready Pen.
If a patient or caregiver is to administer ERELZI, the patient or caregiver should be instructed in injection techniques and how to measure and administer the correct dose [see the ERELZI (etanercept-szzs) “Instructions for Use” insert]. The first injection should be performed under the supervision of a qualified healthcare professional. The patient’s or caregiver’s ability to inject subcutaneously should be assessed. Patients and caregivers should be instructed in the technique, as well as proper syringe and needle disposal, and be cautioned against reuse of needles and syringes.
When using the Sensoready Pen to administer ERELZI, the patient or caregiver should be informed that the window turns green when the injection is complete. After removing the Sensoready Pen, if the window has not turned green, or if it looks like the medicine is still injecting, this means the patient has not received a full dose. The patient or caregiver should be advised to call their healthcare provider immediately.
A puncture-resistant container for disposal of needles, syringes and Sensoready Pens should be used.
Long-term animal studies have not been conducted to evaluate the carcinogenic potential of etanercept products or their effect on fertility.
Available studies with use of etanercept during pregnancy do not reliably support an association between etanercept and major birth defects. Clinical data are available from the Organization of Teratology Information Specialists (OTIS) Pregnancy Registry in women with rheumatic diseases or psoriasis and a Scandinavian study in pregnant women with chronic inflammatory disease. Both the OTIS Registry and the Scandinavian study showed the proportion of liveborn infants with major birth defects was higher for women exposed to etanercept compared to diseased etanercept unexposed women. However, the lack of pattern of major birth defects is reassuring and differences between exposure groups (e.g. disease severity) may have impacted the occurrence of birth defects [see Data]. In animal reproduction studies with pregnant rats and rabbits, no fetal harm or malformations were observed with subcutaneous administration of etanercept during the period of organogenesis at doses that achieved systemic exposures 48 to 58 times the exposure in patients treated with 50 mg etanercept once weekly [see Data].
All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. In the United States, about 2-4% of liveborn babies have a major birth defect and about 15-20% of pregnancies end in miscarriage, regardless of drug exposure.
Fetal/Neonatal Adverse Reactions
The risk of fetal/neonatal adverse reactions with in utero exposure to etanercept products is unknown. Risks and benefits should be considered prior to administering live or live-attenuated vaccines to infants exposed to ERELZI in utero [see Use In Specific Populations].
Human Data
A prospective cohort pregnancy registry conducted by OTIS in the US and Canada between 2000 and 2012 compared the risk of major birth defects in liveborn infants of women with rheumatic diseases or psoriasis exposed to etanercept in the first trimester. The proportion of major birth defects among liveborn infants in the etanercept-exposed (N = 319) and diseased etanercept unexposed cohorts (N = 144) was 9.4% and 3.5%, respectively. The findings showed no statistically significant increased risk of minor birth defects and no pattern of major or minor birth defects.
A Scandinavian study compared the risk of major birth defects in liveborn infants of women with chronic inflammatory disease (CID) exposed to TNF-inhibitors during early pregnancy. Women were identified from the Danish (2004-2012) and Swedish (2006-2012) population based health registers. The proportion of major birth defects among liveborn infants in the etanercept-exposed (N=344) and CID etanercept unexposed cohorts (N = 21,549) was 7.0% and 4.7%, respectively.
Overall, while both the OTIS Registry and Scandinavian study show a higher proportion of major birth defects in etanercept-exposed patients compared to diseased etanercept unexposed patients, the lack of pattern of birth defects is reassuring and differences between exposure groups (e.g. disease severity) may have impacted the occurrence of birth defects.
Three case reports from the literature showed that cord blood levels of etanercept at delivery, in infants born to women administered etanercept during pregnancy, were between 3% and 32% of the maternal serum level.
Animal Data
In embryofetal development studies with etanercept administered during the period of organogenesis to pregnant rats from gestation day (GD) 6 through 20 or pregnant rabbits from GD 6 through 18, there was no evidence of fetal malformations or embryotoxicity in rats or rabbits at respective doses that achieved systemic exposures 48 to 58 times the exposure in patients treated with 50 mg etanercept once weekly (on an AUC basis with maternal subcutaneous doses up to 30 mg/kg/day in rats and 40 mg/kg/day in rabbits). In a peri-and postnatal development study with pregnant rats that received etanercept during organogenesis and the later gestational period from GD 6 through 21, development of pups through post-natal day 4 was unaffected at doses that achieved exposures 48 times the exposure in patients treated with 50 mg etanercept once weekly (on an AUC basis with maternal subcutaneous doses up to 30 mg/kg/day).
Limited data from published literature show that etanercept is present in low levels in human milk and minimally absorbed by a breastfed infant. No data are available on the effects of etanercept products on the breastfed child or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ERELZI and any potential adverse effects on the breastfed child from the drug or from the underlying maternal condition.
Etanercept has been studied in 69 children with moderately to severely active polyarticular JIA aged 2 to 17 years.
Etanercept has not been studied in children < 2 years of age with JIA. For pediatric specific safety information concerning malignancies and inflammatory bowel disease, [see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS].
The clinical significance of infant exposure to etanercept products in utero is unknown. The safety of administering live or live-attenuated vaccines in exposed infants is unknown. Risks and benefits should be considered prior to administering live or live-attenuated vaccines to exposed infants. For pediatric specific safety information concerning vaccinations [see WARNINGS AND PRECAUTIONS and DRUG INTERACTIONS].
A total of 480 RA patients ages 65 years or older have been studied in clinical trials. In PsO randomized clinical trials, a total of 138 out of 1965 patients treated with etanercept or placebo were age 65 or older. No overall differences in safety or effectiveness were observed between these patients and younger patients, but the number of geriatric PsO patients is too small to determine whether they respond differently from younger patients. Because there is a higher incidence of infections in the elderly population in general, caution should be used in treating the elderly.
There have been reports of hypoglycemia following initiation of etanercept therapy in patients receiving medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients.
No dose-limiting toxicities have been observed during clinical trials of etanercept. Single IV doses up to 60 mg/m² (approximately twice the recommended dose) have been administered to healthy volunteers in an endotoxemia study without evidence of dose-limiting toxicities.
ERELZI should not be administered to patients with sepsis.
TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. It plays an important role in the inflammatory processes of RA, polyarticular JIA, PsA and AS and the resulting joint pathology. In addition, TNF plays a role in the inflammatory process of PsO. Elevated levels of TNF are found in involved tissues and fluids of patients with RA, JIA, PsA, AS, and PsO.
Two distinct receptors for TNF (TNFRs), a 55 kilodalton protein (p55) and a 75 kilodalton protein (p75), exist naturally as monomeric molecules on cell surfaces and in soluble forms. Biological activity of TNF is dependent upon binding to either cell surface TNFR.
Etanercept products are dimeric soluble forms of the p75 TNF receptor that can bind TNF molecules. Etanercept products inhibit binding of TNF-α and TNF-β (lymphotoxin alpha [LT-α]) to cell surface TNFRs, rendering TNF biologically inactive. In in vitro studies, large complexes of etanercept with TNF-α were not detected and cells expressing transmembrane TNF (that binds etanercept products) are not lysed in the presence or absence of complement.
Etanercept products can modulate biological responses that are induced or regulated by TNF, including expression of adhesion molecules responsible for leukocyte migration (eg, E-selectin, and to a lesser extent, intercellular adhesion molecule-1 [ICAM-1]), serum levels of cytokines (eg, IL-6), and serum levels of matrix metalloproteinase-3 (MMP-3 or stromelysin). Etanercept products have been shown to affect several animal models of inflammation, including murine collagen-induced arthritis.
After administration of 25 mg of etanercept by a single SC injection to 25 patients with RA, a mean ± standard deviation half-life of 102 ± 30 hours was observed with a clearance of 160 ± 80 mL/hr. A maximum serum concentration (Cmax) of 1.1 ± 0.6 mcg/mL and time to Cmax of 69 ± 34 hours was observed in these patients following a single 25 mg dose. After 6 months of twice weekly 25 mg doses in these same RA patients, the mean Cmax was 2.4 ± 1.0 mcg/mL (N = 23). Patients exhibited a 2-to 7-fold increase in peak serum concentrations and approximately 4-fold increase in AUC0-72 hr (range 1-to 17-fold) with repeated dosing. Serum concentrations in patients with RA have not been measured for periods of dosing that exceed 6 months.
In another study, serum concentration profiles at steady-state were comparable among patients with RA treated with 50 mg etanercept once weekly and those treated with 25 mg etanercept twice weekly. The mean (± standard deviation) Cmax, Cmin, and partial AUC were 2.4 ± 1.5 mcg/mL, 1.2 ± 0.7 mcg/mL, and 297 ± 166 mcg•h/mL, respectively, for patients treated with 50 mg etanercept once weekly (N = 21); and 2.6 ± 1.2 mcg/mL, 1.4 ± 0.7 mcg/mL, and 316 ± 135 mcg•h/mL for patients treated with 25 mg etanercept twice weekly (N = 16).
Patients with JIA (ages 4 to 17 years) were administered 0.4 mg/kg of etanercept twice weekly (up to a maximum dose of 50 mg per week) for up to 18 weeks. The mean serum concentration after repeated SC dosing was 2.1 mcg/mL, with a range of 0.7 to 4.3 mcg/mL. Limited data suggest that the clearance of etanercept is reduced slightly in children ages 4 to 8 years. Population pharmacokinetic analyses predict that the pharmacokinetic differences between the regimens of 0.4 mg/kg twice weekly and 0.8 mg/kg once weekly in JIA patients are of the same magnitude as the differences observed between twice weekly and weekly regimens in adult RA patients.
The mean (± SD) serum steady-state trough concentrations for the 50 mg QW dosing in adult PsO patients were 1.5 ± 0.7 mcg/mL.
In clinical studies with etanercept, pharmacokinetic parameters were not different between men and women and did not vary with age in adult patients. The pharmacokinetics of etanercept were unaltered by concomitant MTX in RA patients. No formal pharmacokinetic studies have been conducted to examine the effects of renal or hepatic impairment on etanercept disposition.
The safety and efficacy of etanercept were assessed in four randomized, double-blind, controlled studies. The results of all four trials were expressed in percentage of patients with improvement in RA using ACR response criteria.
Study I evaluated 234 patients with active RA who were ≥ 18 years old, had failed therapy with at least one but no more than four disease-modifying antirheumatic drugs (DMARDs) (e.g., hydroxychloroquine, oral or injectable gold, MTX, azathioprine, D-penicillamine, sulfasalazine), and had ≥ 12 tender joints, ≥ 10 swollen joints, and either erythrocyte sedimentation rate (ESR) ≥ 28 mm/hr, C-reactive protein (CRP) > 2.0 mg/dL, or morning stiffness for ≥ 45 minutes. Doses of 10 mg or 25 mg etanercept or placebo were administered SC twice a week for 6 consecutive months.
Study II evaluated 89 patients and had similar inclusion criteria to Study I except that patients in Study II had additionally received MTX for at least 6 months with a stable dose (12.5 to 25 mg/week) for at least 4 weeks and they had at least 6 tender or painful joints. Patients in Study II received a dose of 25 mg etanercept or placebo SC twice a week for 6 months in addition to their stable MTX dose.
Study III compared the efficacy of etanercept to MTX in patients with active RA. This study evaluated 632 patients who were ≥ 18 years old with early (≤3 years disease duration) active RA, had never received treatment with MTX, and had ≥ 12 tender joints, ≥ 10 swollen joints, and either ESR ≥ 28 mm/hr, CRP > 2.0 mg/dL, or morning stiffness for ≥ 45 minutes. Doses of 10 mg or 25 mg etanercept were administered SC twice a week for 12 consecutive months. The study was unblinded after all patients had completed at least 12 months (and a median of 17.3 months) of therapy. The majority of patients remained in the study on the treatment to which they were randomized through 2 years, after which they entered an extension study and received open-label 25 mg etanercept. MTX tablets (escalated from 7.5 mg/week to a maximum of 20 mg/week over the first 8 weeks of the trial) or placebo tablets were given once a week on the same day as the injection of placebo or etanercept doses, respectively.
Study IV evaluated 682 adult patients with active RA of 6 months to 20 years duration (mean of 7 years) who had an inadequate response to at least one DMARD other than MTX. Forty-three percent of patients had previously received MTX for a mean of 2 years prior to the trial at a mean dose of 12.9 mg. Patients were excluded from this study if MTX had been discontinued for lack of efficacy or for safety considerations. The patient baseline characteristics were similar to those of patients in Study I. Patients were randomized to MTX alone (7.5 to 20 mg weekly, dose escalated as described for Study III; median dose 20 mg), etanercept alone (25 mg twice weekly), or the combination of etanercept and MTX initiated concurrently (at the same doses as above). The study evaluated ACR response, Sharp radiographic score, and safety.
A higher percentage of patients treated with etanercept and etanercept in combination with MTX achieved ACR 20, ACR 50, and ACR 70 responses and Major Clinical Responses than in the comparison groups. The results of Studies I, II, and III are summarized in Table 6. The results of Study IV are summarized in Table 7.
Table 6: ACR Responses in Placebo-and
Active-Controlled Trials (Percent of Patients)
| Response | Placebo Controlled | Active Controlled | ||||
| Study I | Study II | Study III | ||||
| Placebo N=80 |
Etanercepta N= 78 |
MTX/ Placebo N= 30 |
MTX/ Etanercepta N= 59 |
MTX N=217 |
Etanercepta N= 207 |
|
| ACR 20 | ||||||
| Month 3 | 23% | 62%b | 33% | 66%b | 56% | 62% |
| Month 6 | 11% | 59%b | 27% | 71%b | 58% | 65% |
| Month 12 | NA | NA | NA | NA | 65% | 72% |
| ACR 50 | ||||||
| Month 3 | 8% | 41%b | 0% | 42%b | 24% | 29% |
| Month 6 | 5% | 40%b | 3% | 39%b | 32% | 40% |
| Month 12 | NA | NA | NA | NA | 43% | 49% |
| ACR 70 | ||||||
| Month 3 | 4% | 15%b | 0% | 15%b | 7% | 13%c |
| Month 6 | 1% | 15%b | 0% | 15%b | 14% | 21%c |
| Month 12 | NA | NA | NA | NA | 22% | 25% |
| a 25 mg etanercept SC twice weekly b p< 0.01, etanercept vs placebo c p< 0.05, etanercept vs MTX |
||||||
Table 7: Study IV Clinical Efficacy Results: Comparison of MTX vs Etanercept vs Etanercept in Combination
With MTX in Patients With Rheumatoid Arthritis of 6 Months to 20 Years Duration (Percent of Patients)
| Endpoint | MTX (N= 228) |
Etanercept (N= 223) |
Etanercept/MTX (N= 231) |
| ACR Nab | |||
| Month 12 | 40% | 47% | 63%c |
| ACR 20 | |||
| Month 12 | 59% | 66% | 75%c |
| ACR 50 | |||
| Month 12 | 36% | 43% | 63%c |
| ACR 70 | |||
| Month 12 | 17% | 22% | 40%c |
| Major Clinical Responsed | 6% | 10% | 24%c |
| aValues are medians. bACR N is the percent improvement based on the same core variables used in defining ACR 20, ACR 50, and ACR 70. cp < 0.05 for comparisons of etanercept/MTX vs etanercept alone or MTX alone. dMajor clinical response is achieving an ACR 70 response for a continuous 6-month period. |
|||
The time course for ACR 20 response rates for patients receiving placebo or 25 mg etanercept in Studies I and II is summarized in Figure 1. The time course of responses to etanercept in Study III was similar.
Figure 1 :Time Course of ACR 20 Responses
 |
Among patients receiving etanercept, the clinical responses generally appeared within 1 to 2 weeks after initiation of therapy and nearly always occurred by 3 months. A dose response was seen in Studies I and III: 25 mg etanercept was more effective than 10 mg (10 mg was not evaluated in Study II). Etanercept was significantly better than placebo in all components of the ACR criteria as well as other measures of RA disease activity not included in the ACR response criteria, such as morning stiffness.
In Study III, ACR response rates and improvement in all the individual ACR response criteria were maintained through 24 months of etanercept therapy. Over the 2-year study, 23% of etanercept’s patients achieved a major clinical response, defined as maintenance of an ACR 70 response over a 6-month period.
The results of the components of the ACR response criteria for Study I are shown in Table 8. Similar results were observed for etanercept -treated patients in Studies II and III.
Table 8: Components of ACR Response in Study I
| Parameter (median) | Placebo N=80 |
Etanercepta N=78 |
||
| Baseline | 3 Months | Baseline | 3 Months* | |
| Number of tender jointsb | 34.0 | 29.5 | 31.2 | 10.0f |
| Number of swollen jointsc | 24.0 | 22.0 | 23.5 | 12.6f |
| Physician global assessmentd | 7.0 | 6.5 | 7.0 | 3.0f |
| Patient global assessmentd | 7.0 | 7.0 | 7.0 | 3.0f |
| Paind | 6.9 | 6.6 | 6.9 | 2.4f |
| Disability indexe | 1.7 | 1.8 | 1.6 | 1.0f |
| ESR (mm/hr) | 31.0 | 32.0 | 28.0 | 15.5f |
| CRP (mg/dL) | 2.8 | 3.9 | 3.5 | 0.9f |
| *Results at 6 months showed similar improvement. a25 mg etanercept SC twice weekly. bScale 0-71. cScale 0-68. dVisual analog scale: 0 = best; 10 = worst. eHealth Assessment Questionnaire: 0 = best; 3 = worst; includes eight categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities. fp < 0.01, etanercept vs placebo, based on mean percent change from baseline. |
||||
After discontinuation of etanercept, symptoms of arthritis generally returned within a month. Reintroduction of treatment with etanercept after discontinuations of up to 18 months resulted in the same magnitudes of response as in patients who received etanercept without interruption of therapy, based on results of open-label studies.
Continued durable responses were seen for over 60 months in open-label extension treatment trials when patients received etanercept without interruption. A substantial number of patients who initially received concomitant MTX or corticosteroids were able to reduce their doses or discontinue these concomitant therapies while maintaining their clinical responses.
In Studies I, II, and III, physical function and disability were assessed using the Health Assessment Questionnaire (HAQ). Additionally, in Study III, patients were administered the SF36 Health Survey. In Studies I and II, patients treated with 25 mg etanercept twice weekly showed greater improvement from baseline in the HAQ score beginning in month 1 through month 6 in comparison to placebo (p < 0.001) for the HAQ disability domain (where 0 = none and 3 = severe). In Study I, the mean improvement in the HAQ score from baseline to month 6 was 0.6 (from 1.6 to 1.0) for the 25 mg etanercept group and 0 (from 1.7 to 1.7) for the placebo group. In Study II, the mean improvement from baseline to month 6 was 0.6 (from 1.5 to 0.9) for the etanercept /MTX group and 0.2 (from 1.3 to 1.2) for the placebo/MTX group. In Study III, the mean improvement in the HAQ score from baseline to month 6 was 0.7 (from 1.5 to 0.7) for 25 mg etanercept twice weekly. All subdomains of the HAQ in Studies I and III were improved in patients treated with etanercept.
In Study III, patients treated with 25 mg etanercept twice weekly showed greater improvement from baseline in SF-36 physical component summary score compared to etanercept 10 mg twice weekly and no worsening in the SF-36 mental component summary score. In open-label studies of etanercept, improvements in physical function and disability measures have been maintained for up to 4 years.
In Study IV, median HAQ scores improved from baseline levels of 1.8, 1.8, and 1.8 to 1.1, 1.0, and 0.6 at 12 months in the MTX, etanercept, and etanercept /MTX combination treatment groups, respectively (combination versus both MTX and etanercept, p < 0.01). Twenty-nine percent of patients in the MTX alone treatment group had an improvement of HAQ of at least 1 unit versus 40% and 51% in etanercept alone and etanercept /MTX combination treatment groups, respectively.
In Study III, structural joint damage was assessed radiographically and expressed as change in Total Sharp Score (TSS) and its components, the erosion score and joint space narrowing (JSN) score. Radiographs of hands/wrists and forefeet were obtained at baseline, 6 months, 12 months, and 24 months and scored by readers who were unaware of treatment group. The results are shown in Table 9. A significant difference for change in erosion score was observed at 6 months and maintained at 12 months.
Table 9: Mean Radiographic Change Over 6 and 12 Months
in Study III
| MTX | 25 mg Etanercept | MTX/ Etanercept (95% Confidence Interval*) | P Value | ||
| 12 Months | Total Sharp Score | 1.59 | 1.00 | 0.59 (-0.12, 1.30) | 0.1 |
| Erosion Score | 1.03 | 0.47 | 0.56 (0.11, 1.00) | 0.002 | |
| JSN Score | 0.56 | 0.52 | 0.04 (-0.39, 0.46) | 0.5 | |
| 6 Months | Total Sharp Score | 1.06 | 0.57 | 0.49 (0.06, 0.91) | 0.001 |
| Erosion Score | 0.68 | 0.30 | 0.38 (0.09, 0.66) | 0.001 | |
| JSN Score | 0.38 | 0.27 | 0.11 (-0.14, 0.35) | 0.6 | |
| * 95% confidence intervals for the differences in change scores between MTX and etanercept. | |||||
Patients continued on the therapy to which they were randomized for the second year of Study III. Seventy-two percent of patients had x-rays obtained at 24 months. Compared to the patients in the MTX group, greater inhibition of progression in TSS and erosion score was seen in the 25 mg etanercept group, and, in addition, less progression was noted in the JSN score.
In the open-label extension of Study III, 48% of the original patients treated with 25 mg etanercept have been evaluated radiographically at 5 years. Patients had continued inhibition of structural damage, as measured by the TSS, and 55% of them had no progression of structural damage. Patients originally treated with MTX had further reduction in radiographic progression once they began treatment with etanercept.
In Study IV, less radiographic progression (TSS) was observed with etanercept in combination with MTX compared with etanercept alone or MTX alone at month 12 (Table 10). In the MTX treatment group, 55% of patients experienced no radiographic progression (TSS change ≤ 0.0) at 12 months compared to 63% and 76% in etanercept alone and etanercept /MTX combination treatment groups, respectively.
Table 10: Mean Radiographic
Change in Study IV at 12 Months (95% Confidence Interval)
| MTX (N=212)* |
Etanercept (N=212)* |
Etanercept/MTX (N=218)* |
|
| Total Sharp Score (TSS) | 2.80 (1.08, 4.51) |
0.52a (-0.10, 1.15) |
-0.54b,c (-1.00, -0.07) |
| Erosion Score (ES) | 1.68 (0.61, 2.74) |
0.21a (-0.20, 0.61) |
-0.30b (-0.65, 0.04) |
| Joint Space Narrowing (JSN) Score | 1.12 (0.34, 1.90) |
0.32 (0.00, 0.63) |
-0.23b,c (-0.45, -0.02) |
| *Analyzed radiographic ITT population. ap < 0.05 for comparison of etanercept vs MTX. bp < 0.05 for comparison of etanercept/MTX vs MTX. cp < 0.05 for comparison of etanercept/MTX vs etanercept. |
|||
The safety and efficacy of 50 mg etanercept (two 25 mg SC injections) administered once weekly were evaluated in a double-blind, placebo-controlled study of 420 patients with active RA. Fifty-three patients received placebo, 214 patients received 50 mg etanercept once weekly, and 153 patients received 25 mg etanercept twice weekly. The safety and efficacy profiles of the two etanercept treatment groups were similar.
The safety and efficacy of
etanercept were assessed in a 2-part study in 69 children with polyarticular
JIA who had a variety of JIA onset types. Patients ages 2 to 17 years with
moderately to severely active polyarticular JIA refractory to or intolerant of
MTX were enrolled; patients remained on a stable dose of a single nonsteroidal
anti-inflammatory drug and/or prednisone (≤0.2 mg/kg/day or 10 mg maximum). In part 1, all patients received 0.4 mg/kg
(maximum 25 mg per dose) etanercept SC twice weekly. In part 2, patients with a clinical response at day 90 were randomized to remain on etanercept or receive placebo for 4 months and assessed for disease flare. Responses were measured using the JIA Definition of Improvement (DOI), defined as ≥ 30% improvement in at least three of six and ≥ 30% worsening in no more
than one of the six JIA core set criteria, including active joint count, limitation of motion, physician and patient/parent global assessments, functional assessment, and ESR. Disease flare was defined as a ≥ 30% worsening in three of the six JIA core set criteria and ≥ 30% improvement in not more than one of the six JIA core set criteria and a minimum of two active joints.
In part 1 of the study, 51 of69 (74%) patients demonstrated a clinical response and entered part 2. In part 2, 6 of 25 (24%) patients remaining on etanercept experienced a disease flare compared to 20 of 26 (77%) patients receiving placebo (p = 0.007). From the start of part 2, the median time to flare was ≥ 116 days for patients who received etanercept and 28 days for patients who received placebo. Each component of the JIA core set criteria worsened in the arm that received placebo and remained stable or improved in the arm that continued on etanercept. The data suggested the possibility of a higher flare rate among those patients with a higher baseline ESR. Of patients who demonstrated a clinical response at 90 days and entered part 2 of the study, some of the patients remaining on etanercept continued to improve from month 3 through month 7, while those who received placebo did not improve.
The majority of JIA patients who developed a disease flare in part 2 and reintroduced etanercept treatment up to 4 months after discontinuation re-responded to etanercept therapy in open-label studies. Most of the responding patients who continued etanercept therapy without interruption have maintained responses for up to 48 months.
Studies have not been done in patients with polyarticular JIA to assess the effects of continued etanercept therapy in patients who do not respond within 3 months of initiating etanercept therapy, or to assess the combination of etanercept with MTX.
The safety and efficacy of etanercept were assessed in a randomized, double-blind, placebo-controlled study in 205 patients with PsA. Patients were between 18 and 70 years of age and had active PsA (≥ 3 swollen joints and ≥ 3 tender joints) in one or more of the following forms: (1) distal interphalangeal (DIP) involvement (N = 104); (2) polyarticular arthritis (absence of rheumatoid nodules and presence of psoriasis; N = 173); (3) arthritis mutilans (N = 3); (4) asymmetric psoriatic arthritis (N = 81); or (5) ankylosing spondylitis-like (N = 7). Patients also had plaque psoriasis with a qualifying target lesion ≥ 2 cm in diameter. Patients on MTX therapy at enrollment (stable for ≥ 2 months) could continue at a stable dose of ≤ 25 mg/week MTX. Doses of 25 mg etanercept or placebo were administered SC twice a week during the initial 6month double-blind period of the study. Patients continued to receive blinded therapy in an up to 6-month maintenance period until all patients had completed the controlled period. Following this, patients received open-label 25 mg etanercept twice a week in a 12-month extension period.
Compared to placebo, treatment with etanercept resulted in significant improvements in measures of disease activity (Table 11).
Table 11: Components of Disease Activity in Psoriatic
Arthritis
| Parameter (median) | Placebo N= 104 |
Etanercepta N= 101 |
||
| Baseline | 6 Months | Baseline | 6 Months | |
| Number of tender jointsb | 17.0 | 13.0 | 18.0 | 5.0 |
| Number of swollen jointsc | 12.5 | 9.5 | 13.0 | 5.0 |
| Physician global assessmentd | 3.0 | 3.0 | 3.0 | 1.0 |
| Patient global assessmentd | 3.0 | 3.0 | 3.0 | 1.0 |
| Morning stiffness (minutes) | 60 | 60 | 60 | 15 |
| Paind | 3.0 | 3.0 | 3.0 | 1.0 |
| Disability indexe | 1.0 | 0.9 | 1.1 | 0.3 |
| CRP (mg/dL)f | 1.1 | 1.1 | 1.6 | 0.2 |
| ap < 0.001 for all comparisons between
etanercept and placebo at 6 months. bScale 0-78. cScale 0-76. dLikert scale: 0 = best; 5 = worst. eHealth Assessment Questionnaire: 0 = best; 3 = worst; includes eight categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities. fNormal range: 0-0.79 mg/dL. |
||||
Among patients with PsA who received etanercept, the clinical responses were apparent at the time of the first visit (4 weeks) and were maintained through 6 months of therapy. Responses were similar in patients who were or were not receiving concomitant MTX therapy at baseline. At 6 months, the ACR 20/50/70 responses were achieved by 50%, 37%, and 9%, respectively, of patients receiving etanercept, compared to 13%, 4%, and 1%, respectively, of patients receiving placebo. Similar responses were seen in patients with each of the subtypes of PsA, although few patients were enrolled with the arthritis mutilans and ankylosing spondylitis-like subtypes. The results of this study were similar to those seen in an earlier single-center, randomized, placebo-controlled study of 60 patients with PsA.
The skin lesions of psoriasis were also improved with etanercept, relative to placebo, as measured by percentages of patients achieving improvements in the Psoriasis Area and Severity Index (PASI). Responses increased over time, and at 6 months, the proportions of patients achieving a 50% or 75% improvement in the PASI were 47% and 23%, respectively, in the etanercept group (N = 66), compared to 18% and 3%, respectively, in the placebo group (N = 62). Responses were similar in patients who were or were not receiving concomitant MTX therapy at baseline.
Radiographic changes were also assessed in the PsA study. Radiographs of hands and wrists were obtained at baseline and months 6, 12, and 24. A modified Total Sharp Score (TSS), which included distal interphalangeal joints (ie, not identical to the modified TSS used for RA) was used by readers blinded to treatment group to assess the radiographs. Some radiographic features specific to PsA (eg, pencil-and-cup deformity, joint space widening, gross osteolysis, and ankylosis) were included in the scoring system, but others (eg, phalangeal tuft resorption, juxtaarticular and shaft periostitis) were not.
Most patients showed little or no change in the modified TSS during this 24-month study (median change of 0 in both patients who initially received etanercept or placebo). More placebo-treated patients experienced larger magnitudes of radiographic worsening (increased TSS) compared to etanercept treatment during the controlled period of the study. At 12 months, in an exploratory analysis, 12% (12 of 104) of placebo patients compared to none of the 101 of etanercept-treated patients had increases of 3 points or more in TSS. Inhibition of radiographic progression was maintained in patients who continued on etanercept during the second year. Of the patients with 1-year and 2-year x-rays, 3% (2 of 71) had increases of 3 points or more in TSS at 1 and 2 years.
In the PsA study, physical function and disability were assessed using the HAQ Disability Index (HAQ-DI) and the SF-36 Health Survey. Patients treated with 25 mg etanercept twice weekly showed greater improvement from baseline in the HAQ-DI score (mean decreases of 54% at both months 3 and 6) in comparison to placebo (mean decreases of 6% at both months 3 and 6) (p < 0.001). At months 3 and 6, patients treated with etanercept showed greater improvement from baseline in the SF-36 physical component summary score compared to patients treated with placebo, and no worsening in the SF-36 mental component summary score. Improvements in physical function and disability measures were maintained for up to 2 years through the open-label portion of the study.
The safety and efficacy of etanercept were assessed in a randomized, double-blind, placebo-controlled study in 277 patients with active AS. Patients were between 18 and 70 years of age and had AS as defined by the modified New York Criteria for Ankylosing Spondylitis. Patients were to have evidence of active disease based on values of ≥ 30 on a 0-100 unit Visual Analog Scale (VAS) for the average of morning stiffness duration and intensity, and two of the following three other parameters: a) patient global assessment, b) average of nocturnal and total back pain, and c) the average score on the Bath Ankylosing Spondylitis Functional Index (BASFI). Patients with complete ankylosis of the spine were excluded from study participation. Patients taking hydroxychloroquine, sulfasalazine, methotrexate, or prednisone (≤ 10 mg/day) could continue these drugs at stable doses for the duration of the study. Doses of 25 mg etanercept or placebo were administered SC twice a week for 6 months.
The primary measure of efficacy was a 20% improvement in the Assessment in Ankylosing Spondylitis (ASAS) response criteria. Compared to placebo, treatment with etanercept resulted in improvements in the ASAS and other measures of disease activity (Figure 2 and Table 12).
Figure 2 : ASAS 20 Responses in Ankylosing Spondylitis
 |
At 12 weeks, the ASAS 20/50/70 responses were achieved by 60%, 45%, and 29%, respectively, of patients receiving etanercept, compared to 27%, 13%, and 7%, respectively, of patients receiving placebo (p ≤ 0.0001, etanercept vs placebo). Similar responses were seen at Week 24. Responses were similar between those patients receiving concomitant therapies at baseline and those who were not. The results of this study were similar to those seen in a single-center, randomized, placebo-controlled study of 40 patients and a multicenter, randomized, placebo-controlled study of 84 patients with AS.
Table 12: Components of Ankylosing Spondylitis Disease
Activity
| Median values at time points | Placebo N=139 |
Etanercepta N=138 |
||
| Baseline | 6 Months | Baseline | 6 Months | |
| ASAS response criteria Patient global assessmentb | 63 | 56 | 63 | 36 |
| Back painc | 62 | 56 | 60 | 34 |
| BASFId | 56 | 55 | 52 | 36 |
| Inflammatione | 64 | 57 | 61 | 33 |
| Acute phase reactants CRP (mg/dL)f | 2.0 | 1.9 | 1.9 | 0.6 |
| Spinal mobility (cm): Modified Schober’s test | 3.0 | 2.9 | 3.1 | 3.3 |
| Chest expansion | 3.2 | 3.0 | 3.3 | 3.9 |
| Occiput-to-wall measurement | 5.3 | 6.0 | 5.6 | 4.5 |
| ap < 0.0015 for all comparisons between
etanercept and placebo at 6 months. P values for continuous endpoints were
based on percent change from baseline. bMeasured on a Visual Analog Scale (VAS) with 0 = “none” and 100 = “severe”. cAverage of total nocturnal and back pain scores, measured on a VAS with 0 = “no pain” and 100 = “most severe pain”. dBath Ankylosing Spondylitis Functional Index (BASFI), average of 10 questions. eInflammation represented by the average of the last 2 questions on the 6-question Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). fC-reactive protein (CRP) normal range: 0-1.0 mg/dL. |
||||
The safety and efficacy of etanercept were assessed in two randomized, double-blind, placebo-controlled studies in adults with chronic stable PsO involving ≥ 10% of the body surface area, a minimum Psoriasis Area and Severity Index (PASI) score of 10 and who had received or were candidates for systemic antipsoriatic therapy or phototherapy. Patients with guttate, erythrodermic, or pustular psoriasis and patients with severe infections within 4 weeks of screening were excluded from study. No concomitant major antipsoriatic therapies were allowed during the study.
Study I evaluated 672 patients who received placebo or etanercept SC at doses of 25 mg once a week, 25 mg twice a week, or 50 mg twice a week for 3 months. After 3 months, patients continued on blinded treatments for an additional 3 months during which time patients originally randomized to placebo began treatment with blinded etanercept at 25 mg twice weekly (designated as placebo/etanercept in Table 13); patients originally randomized to etanercept continued on the originally randomized dose (designated as etanercept/etanercept groups in Table 13).
Study II evaluated 611 patients who received placebo or etanercept SC at doses of 25 mg or 50 mg twice a week for 3 months. After 3 months of randomized, blinded treatment, patients in all three arms began receiving open-label etanercept at 25 mg twice weekly for 9 additional months.
Response to treatment in both studies was assessed after 3 months of therapy and was defined as the proportion of patients who achieved a reduction in PASI score of at least 75% from baseline. The PASI is a composite score that takes into consideration both the fraction of body surface area affected and the nature and severity of psoriatic changes within the affected regions (induration, erythema and scaling).
Other evaluated outcomes included the proportion of patients who achieved a score of “clear” or “minimal” by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline. The sPGA is a 6-category scale ranging from “5 = severe” to “0 = none” indicating the physician’s overall assessment of the PsO severity focusing on induration, erythema and scaling. Treatment success of “clear” or “minimal” consisted of none or minimal elevation in plaque, up to faint red coloration in erythema and none or minimal fine scale over < 5% of the plaque.
Patients in all treatment groups and in both studies had a median baseline PASI score ranging from 15 to 17, and the percentage of patients with baseline sPGA classifications ranged from 54% to 66% for moderate, 17% to 26% for marked and 1% to 5% for severe. Across all treatment groups, the percentage of patients who previously received systemic therapy for PsO ranged from 61% to 65% in Study I and 71% to 75% in Study II, and those who previously received phototherapy ranged from 44% to 50% in Study I and 72% to 73% in Study II.
More patients randomized to etanercept than placebo achieved at least a 75% reduction from baseline PASI score (PASI 75) with a dose response relationship across doses of 25 mg once a week, 25 mg twice a week and 50 mg twice a week (Tables 13 and 14). The individual components of the PASI (induration, erythema and scaling) contributed comparably to the overall treatment-associated improvement in PASI.
Table 13: Study I Outcomes at 3 and 6 Months
| Placebo/ Etanercept 25 mg BIW (N= 168) |
Etanercept/Etanercept | |||
| 25 mg QW (N= 169) |
25 mg BIW (N= 167) |
50 mg BIW (N= 168) |
||
| 3 Months | ||||
| PASI 75 n (%) | 6 (4%) | 23 (14%)a | 53 (32%)b | 79 (47%)b |
| Difference (95% CI) | 10% (4, 16) | 28% (21, 36) | 43% (35, 52) | |
| sPGA, ‘clear’ or ‘minimal’ n (%) | 8 (5%) | 36 (21%)b | 53 (32%)b | 79 (47%)b |
| Difference (95% CI) | 17% (10, 24) | 27% (19, 35) | 42% (34, 50) | |
| PASI 50 n (%) | 24 (14%) | 62 (37%)b | 90 (54%)b | 119 (71%)b |
| Difference (95% CI) | 22% (13, 31) | 40% (30, 49) | 57% (48, 65) | |
| 6 Months PASI 75 n (%) | 55 (33%) | 36 (21%) | 68 (41%) | 90 (54%) |
| ap = 0.001 compared with placebo. bp < 0.0001 compared with placebo. |
||||
Table 14: Study II Outcomes at 3 Months
| Placebo (N= 204) |
Etanercept | ||
| 25 mg BIW (N= 204) |
50 mg BIW (N= 203) |
||
| PASI 75 n (%) | 6 (3%) | 66 (32%)a | 94 (46%)a |
| Difference (95% CI) | 29% (23, 36) | 43% (36, 51) | |
| sPGA, “clear” or minimal” n (%) | 7 (3%) | 75 (37%)a | 109 (54%)a |
| Difference (95% CI) | 34% (26, 41) | 50% (43, 58) | |
| PASI 50 n (%) | 18 (9%) | 124 (61%)a | 147 (72%)a |
| Difference (95% CI) | 52% (44, 60) | 64% (56, 71) | |
| ap < 0.0001 compared with placebo. | |||
Among PASI 75 achievers in both studies, the median time to PASI 50 and PASI 75 was approximately 1 month and approximately 2 months, respectively, after the start of therapy with either 25 or 50 mg twice a week.
In Study I, patients who achieved PASI 75 at month 6 were entered into a study drug withdrawal and retreatment period. Following withdrawal of study drug, these patients had a median duration of PASI 75 of between 1 and 2 months.
In Study I, among patients who were PASI 75 responders at 3 months, retreatment with their original blinded etanercept dose after discontinuation of up to 5 months resulted in a similar proportion of responders as in the initial double-blind portion of the study.
In Study II, most patients initially randomized to 50 mg twice a week continued in the study after month 3 and had their etanercept dose decreased to 25 mg twice a week. Of the 91 patients who were PASI 75 responders at month 3, 70 (77%) maintained their PASI 75 response at month 6.
REFERENCES
1. National Cancer Institute. Surveillance, Epidemiology, and End Results Database (SEER) Program. SEER Incidence Crude Rates, 13 Registries, 1992-2002.
2. Bröms G, Granath F, Ekbom A, et al. Low Risk of Birth Defects for Infants Whose Mothers Are Treated With Anti-Tumor Necrosis Factor Agents During Pregnancy. Clin Gastroenterol Hepatol. 2016;14:234-241.e5
ERELZI
(eh rel’ zee)
(etanercept-szzs) injection, for Subcutaneous Use
Read the Medication Guide that comes with ERELZI before you start using it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking with your healthcare provider about your medical condition or treatment. It is important to remain under your healthcare provider’s care while using ERELZI. ERELZI is a prescription medicine called a Tumor Necrosis Factor (TNF) blocker that affects your immune system.
What is the most important information I should know about ERELZI?
ERELZI may cause serious side effects, including:
1. Risk of Infection
2. Risk of Cancer
1. Risk of Infection
ERELZI can lower the ability of your immune system to fight infections. Some people have serious infections while taking etanercept products. These infections include tuberculosis (TB), and infections caused by viruses, fungi, or bacteria that spread throughout their body. Some people have died from these infections.
2. Risk of Cancer
Before starting ERELZI, be sure to talk to your healthcare provider:
ERELZI may not be right for you. Before starting ERELZI, tell your healthcare provider about all of your medical conditions, including:
Infections. Tell your healthcare provider if you:
Also, before starting ERELZI, tell your healthcare provider:
Keep a list of all your medications with you to show your healthcare provider and pharmacist each time you get a new medicine. Ask your healthcare provider if you are not sure if your medicine is one listed above.
Other important medical information you should tell your healthcare provider before starting ERELZI, includes if you:
See “What are the possible side effects of ERELZI?” below for more information.
What is ERELZI?
ERELZI is a prescription medicine called a Tumor Necrosis Factor (TNF) blocker. ERELZI is used to treat:
You may continue to use other medicines that help treat your condition while taking ERELZI, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and prescription steroids, as recommended by your healthcare provider.
ERELZI can help reduce joint damage and the signs and symptoms of the above-mentioned diseases. People with these diseases have too much of a protein called tumor necrosis factor (TNF), which is made by your immune system. ERELZI can reduce the effect of TNF in the body and block the damage that too much TNF can cause, but it can also lower the ability of your immune system to fight infections. See “What is the most important information I should know about ERELZI?” and “What are the possible side effects of ERELZI?”
Who should not use ERELZI?
Do not use ERELZI if you:
How should I use ERELZI?
What are the possible side effects of ERELZI?
ERELZI can cause serious side effects including:
Common side effects of ERELZI include:
These are not all the side effects with ERELZI. Tell your healthcare provider about any side effect that bothers you or does not go away.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store ERELZI?
General information about the safe and effective use of ERELZI.
Medicines are sometimes prescribed for purposes not mentioned in a Medication Guide. Do not use ERELZI for a condition for which it was not prescribed. Do not give ERELZI to other people, even if they have the same condition. It may harm them.
This Medication Guide summarizes the most important information about ERELZI. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about ERELZI that was written for healthcare professionals.
What are the ingredients in ERELZI?
Single-dose Prefilled Syringe and the Single-dose Prefilled Sensoready Pen:
Active Ingredient: etanercept-szzs
Inactive Ingredients: sodium citrate, sucrose, sodium chloride, lysine, citric acid
Instructions for Use
ERELZI
(eh rel' zee)
(etanercept-szzs) Sensoready® Pen
Be sure that you read, understand, and follow this Instructions for Use before injecting ERELZI. Your healthcare provider should show you how to prepare and inject ERELZI properly using the ERELZI SensoreadyPen before you use it for the first time. Talk to your healthcare provider if you have any questions.
Important:
Do not use the ERELZI Sensoready Pen if either the seal on the outer carton or the seal on the pen isbroken. Keep the ERELZI Sensoready Pen in the sealed outer carton until you are ready to use it.
Inject ERELZI 15 to 30 minutes after taking it out of the refrigerator.
How should I store ERELZI?
Keep ERELZI and all medicines out of the reach of children.
ERELZI Sensoready Pen parts (see Figure A):
Figure A
 |
The ERELZI Sensoready Pen is shown above with the cap removed. Do not remove the cap until you are ready to inject.
What you need for your injection:
Included in your carton:
A new ERELZI Sensoready Pen (see Figure B).
Figure B
 |
Each ERELZI Sensoready Pen contains 50 mg/mLof ERELZI.
Not included in your carton (see Figure C):
Figure C
 |
See “How should I dispose of used ERELZI Sensoready Pen?” at the end of this Instructions for Use.
Before your injection:
Take the ERELZI Sensoready Pen out of the refrigerator 15 to 30 minutes before injecting to allow it to reach room temperature. Do not try to warm the ERELZI Sensoready Pen by using a heat source such as hot water or a microwave.
Step 1. Important safety checks before you inject (see Figure D):
Figure D
 |
Contact your pharmacist if the ERELZI Sensoready Pen fails any of these checks.
Step 2. Choose your injection site:
Figure E
 |
Figure F
 |
Step 3. Cleaning your injection site:
Figure G
 |
Your injection:
Step 4. Removing the cap:
Figure H
 |
Step 5. Holding your Sensoready Pen:
Figure I
 |
Correct and Incorrect
 |
Important: During the injection you will hear 2 loud clicks:
You must keep holding the ERELZI Sensoready Pen firmly against your skin until you see a green indicator fill the viewing window and stop moving.
Step 6. Starting your injection:
Press the ERELZI Sensoready Pen firmly against the skin to start the injection (see Figure J).
Figure J
 |
Step 7. Completing your injection:
Figure K
 |
After your injection:
Step 8. Check the green indicator to make sure it fills the viewing window (see Figure L):
Figure L
 |
How should I dispose of used ERELZI Sensoready Pens?
Step 9. Put your used ERELZI Sensoready Pens in an FDA-cleared sharps disposal container right away after use (see Figure M). Do not throw away (dispose of) ERELZI Sensoready Pens in your household trash.
Figure M
 |
If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:
When your sharps container is almost full, you will need to follow your community guidelines, for the right wayto dispose of your sharps disposal container. There may be a state or local laws about how you should throwaway used syringes, needles and ERELZI Sensoready Pens. For more information about safe sharps disposal, and for specific information about sharps disposal, in the state that you live in, go to FDA’s website at:http://www.fda.gov/safesharpsdisposal.
Do not dispose of your used sharps disposal container in your household trash unless your communityguidelines permit this. Do not recycle your used sharps disposal container.
This Instructions for Use has been approved by the U.S. Food and Drug Administration.
Instructions for Use
ERELZI
(eh rel' zee)
(etanercept-szzs) Prefilled Syringe
Important:
To help avoid a possible infection, you should follow these instructions.
Be sure that you read, understand, and follow this Instructions for Use before injecting ERELZI. Your healthcare provider should show you how to prepare and inject ERELZI properly using the prefilled syringe before you use it for the first time. Talk to your healthcare provider if you have any questions.
Important:
How should I store ERELZI?
Keep ERELZI and all medicines out of the reach of children.
ERELZI prefilled syringe parts (see Figure A).
Figure A: ERELZI prefilled syringe with needle guard
and finger flange
 |
Figure B: Device Activated – Do Not Use
 |
Figure C: Device Ready to Be Used
 |
What you need for your injection:
Included in the carton:
A new ERELZI prefilled syringe (see Figure C)
Each prefilled syringe contains 25 mg/0.5 mL or 50 mg/mL of ERELZI.
Not included in the carton (see Figure D):
Figure D
 |
See “How should I dispose of used ERELZI prefilled syringes?” at the end of this Instructions for Use.
Step 1: Preparing the ERELZI Prefilled Syringe
Step 2: Choosing and Preparing an Injection Site
1. The recommended site is the front of your thighs. You may also use the lower abdomen, but not the area 2 inches (5 cm) around your navel (belly button) (see Figure E).
Figure E
 |
2. Choose a different site each time you give yourself an injection.
3. Do not inject into areas where the skin is tender, bruised, red or hard. Avoid areas with scars or stretch marks.
4. If you have psoriasis, do not inject directly into any raised, thick, red, or scaly skin patches or lesions.
5. If a caregiver or healthcare provider is giving you your injection, they may also inject into your outer upper arm (see Figure F).
Figure F
 |
6. Using a circular motion, clean the injection site with the alcohol wipe. Leave it to dry before injecting. Do not touch the cleaned area again before injecting.
Step 3: Injecting ERELZI Using a Prefilled Syringe
Only remove the needle cap when you are ready to use the ERELZI prefilled syringe.
1. Carefully remove the needle cap from the ERELZI prefilled syringe (see Figure G). Throw away the needle cap. You may see a drop of liquid at the end of the needle. This is normal.
Figure G
 |
2. With one hand gently pinch the skin at the injection site. With your other hand insert the needle into your skin as shown (see Figure H). Push the needle all the way in to make sure that you inject your full dose.
Figure H
 |
3. Hold the ERELZI prefilled syringe as shown (see Figure I). Slowly press down on the plunger as far as itwill go, so that the plunger head is completely between the needle guard wings.
Figure I
 |
4. Keep the plunger fully pressed down while you hold the syringe in place for 5 seconds.
5. Keep the plunger fully pressed down while you carefully pull the needle straight out from the injection site (see Figure J).
Figure J
 |
6. Slowly release the plunger and allow the needle guard to automatically cover the exposed needle (see Figure K).
Figure K
 |
7. There may be a small amount of blood at the injection site. You can press a cotton ball or gauze over the injection site and hold it for 10 seconds. Do not rub the injection site. You may cover the injection site with a small adhesive bandage, if needed.
How should I throw away used ERELZI prefilled syringes?
Put your used prefilled syringes in an FDA-cleared sharps disposal container right away after use (see Figure L). Do not throw away (dispose of) ERELZI prefilled syringes in your household trash.
If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:
Figure L
 |
When your sharps disposal container is almost full, you will need tofollow your community guidelines for the right way to dispose of yoursharps disposal container. There may be state or local laws about how youshould throw away used needles, syringes, and prefilled syringes. Formore information about safe sharps disposal, and for specific information about sharps disposal in the state thatyou live in, go to the FDA’s website at: http://www.fda.gov/safesharpsdisposal
Do not dispose of your used sharps disposal container in your household trash unless your communityguidelines permit this. Do not recycle your used sharps disposal container.
This Instructions for Use has been approved by the U.S. Food and Drug Administration.
